Activity-Based Therapeutic Algorithm for Folliculitis Decalvans: A Practical Tool for Effective Management

    Anna Bolzon, Antonella Tosti
    Image of study
    TLDR A new treatment plan helps manage folliculitis decalvans effectively.
    The study presents a therapeutic algorithm for managing folliculitis decalvans (FD), a common form of scarring alopecia. It emphasizes the importance of accurate diagnosis and management to prevent irreversible scarring and systemic complications. The algorithm is based on disease activity, assessed using the Investigator's Global Assessment score and the Trichoscopy Activity Scale. Management is divided into acute and mild inflammatory phases, with oral antibiotics and corticosteroids recommended for the acute phase, and oral isotretinoin for mild activity. The study highlights the lack of clinical trials for FD treatments and the off-label use of medications, while also cautioning against the use of antibiotics essential for systemic infections due to resistance risks. The algorithm includes additional systemic and topical therapies, offering a structured guideline for dermatologists and paving the way for future research on FD treatment strategies.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 83 results

    Similar Research

    5 / 1000+ results
      Primary Cicatricial Alopecias

      research Primary Cicatricial Alopecias

      1 citations , April 2010 in “Expert Review of Dermatology”
      The document concludes that early diagnosis and treatment are crucial for managing rare hair loss disorders and that more research is needed to improve treatment strategies.
      Cicatricial Alopecia: Overview and Treatment Recommendations

      research Cicatricial Alopecia: Overview and Treatment Recommendations

      23 citations , April 2018 in “Journal der Deutschen Dermatologischen Gesellschaft”
      Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.